A Next-Generation Bispecific Nanobody Immunoconjugate Targeting ERBB2 and TFRC for Metastatic Breast Cancer

VHH-P334 is a humanized nanobody-based immunoconjugate engineered to target both erb-b2 receptor tyrosine kinase 2 (ERBB2) and transferrin receptor (TFRC). The molecule strategically combines a variable heavy chain antibody domain directed against TFRC with the heavy chain of a humanized monoclonal antibody specific for ERBB2, linked via a Gly-Ser sequence. Developed in Chinese hamster ovary cells and currently in the Biological Testing stage, VHH-P334 holds promise as an innovative therapeutic option for metastatic breast cancer by simultaneously addressing two validated cancer targets.

Licensing Opportunity

VHH-P334 is available for out-licensing opportunities. We invite collaboration with partners interested in accelerating its clinical development and commercialization for metastatic breast cancer and related indications.

Development Phase

Modality

VHH-P334 utilizes a dual-targeting immunoconjugate modality, integrating a humanized single-domain nanobody against TFRC with the heavy chain of a humanized IgG1 kappa antibody specific for ERBB2 via a flexible Gly-Ser linker. Expression in Chinese hamster ovary cells supports scalability and consistency for clinical development. The nanobody architecture confers compact size and exceptional binding specificity, facilitating enhanced tumor penetration and stability—key advantages for addressing metastatic breast cancer, where tissue accessibility and microenvironment diversity often limit the efficacy of traditional antibody therapies. This modality opens new opportunities for efficient tumor targeting and combinatorial blockade of tumor growth and survival pathways.

Target

ERBB2 and TFRC are two extensively validated molecular targets in oncology. ERBB2 is a receptor tyrosine kinase integral to cell signaling and proliferation, commonly overexpressed in aggressive forms of breast cancer, including the metastatic setting. TFRC is a transmembrane glycoprotein central to iron uptake and cellular metabolism, found at high densities on rapidly dividing cells and malignancies. ERBB2 and TFRC are predominantly expressed on tumor cells within breast and other solid tumors, with limited expression in normal tissues, allowing therapeutic selectivity. Targeting both ERBB2 and TFRC equips VHH-P334 with the capacity to disrupt proliferative signaling and tumor metabolic dependencies, offering strategic benefit in overcoming therapeutic resistance and tumor heterogeneity inherent in metastatic breast cancer. This synergistic dual-targeting approach enhances the asset value of VHH-P334 for addressing unmet needs in cancer therapy.

Mechanism of Action

VHH-P334 functions by selectively binding ERBB2 and TFRC on the surface of tumor cells. Engagement with ERBB2 leads to inhibition of its downstream signaling pathways, thereby suppressing cell proliferation and survival. Simultaneous targeting of TFRC disrupts cellular iron acquisition, curbing metabolic support essential for tumor growth. The nanobody component against TFRC, fused to the heavy chain of an anti-ERBB2 IgG1, enables high-affinity and precise recognition of both targets. As a signal transduction modulator, VHH-P334 has the potential to elicit additive or synergistic anti-tumor effects. The nanobody platform also enables future development possibilities such as creating antibody-drug conjugates or bispecific constructs for broader oncological applications.

Metastatic Breast Cancer

Metastatic breast cancer represents a significant global health burden, being one of the leading causes of cancer-related mortality in women worldwide. Despite intensive research advances, long-term survival remains limited for patients with distant metastatic disease. Current mainstays of treatment include chemotherapy, endocrine therapy, immunotherapy, and targeted approaches aimed at specific molecular alterations such as those involving ERBB2. However, these therapies often encounter challenges such as acquired resistance, adverse effects, and limited efficacy in heterogeneous or heavily pretreated populations. There remains a clear unmet medical need for innovative interventions capable of overcoming tumor adaptation and providing durable responses. With its dual-targeting mechanism and advanced nanobody architecture, VHH-P334 addresses crucial resistance pathways and heterogeneity in metastatic breast cancer, offering the promise of improved patient outcomes and expanded therapeutic options in a population with otherwise limited choices.